Investigative Review of Centene Corporation

,

,

as needed. – No markdown code fences. – Do not repeat earlier sections. Already written section titles (do not repeat): 1. The ‘No-Fault’ Strategy: Analyzing Centene’s $1. 25 Billion Settlement Reserve Current section focus: – Deep dive into the specific mechanics of how Envolve Pharmacy Solutions and Health Net Pharmacy Solutions were used. – Explain the ” ” of fees. – Detail the relationship with CVS Caremark as the third-party administrator. – Analyze the Ohio and Mississippi specific allegations regarding this structure. – Explain “spread pricing” in technical detail. Search queries needed: 1. Envolve Pharmacy Solutions Health Net Pharmacy Solutions subcontractor structure. 2. Centene CVS Caremark agreement details Medicaid. 3. Ohio Attorney General Centene lawsuit complaint pdf details. 4. Mississippi Centene settlement spread pricing mechanics. 5. How Centene used two PBMs to costs. 6. ” fees” Centene Medicaid allegations. 7. Envolve Health Net “administrative service provider” transition. Let’s start with the search.

Anatomy of the 'Layering' Scheme: Envolve Pharmacy Solutions and Subcontractor Obfuscation

The Architecture of Obfuscation: Inside the Envolve-Health Net Structure

The core of the allegations against Centene Corporation revolves around a sophisticated structural arrangement known as “.” This method allowed the company to artificially pharmacy costs charged to state Medicaid programs while simultaneously concealing the actual payments made to pharmacies. At the center of this scheme sat Envolve Pharmacy Solutions, a wholly-owned subsidiary of Centene. While Centene presented Envolve as a distinct entity providing essential pharmacy benefit management (PBM) services, investigations by state attorneys general revealed that Envolve frequently functioned as a pass-through shell. The actual claims processing and network management were frequently subcontracted to third-party giants, primarily CVS Caremark. This redundant created a “spread pricing” loop where Centene could generate profit from taxpayer funds for medical care.

State Medicaid programs operate under a managed care model. The state pays a Managed Care Organization (MCO), in this case, Centene’s local subsidiary, such as Buckeye Health Plan in Ohio or Sunflower Health Plan in Kansas, a capitated rate per member. The MCO is then responsible for paying healthcare providers. To manage prescription drug benefits, the MCO hires a PBM. In a transparent system, the PBM negotiates drug prices, pays the pharmacy, and bills the MCO for the actual cost plus a defined administrative fee. Centene’s model deviated from this standard. Instead of hiring an external PBM directly, Centene’s MCOs contracted with Centene’s own subsidiaries, Envolve Pharmacy Solutions and Health Net Pharmacy Solutions.

This internal contracting created an immediate conflict of interest. The MCO (Centene) and the PBM (Envolve) shared the same parent company and the same profit motives. Because the contracts were internal, they absence the competitive tension that keeps prices in check. Envolve then contracted with a third-party administrator, such as CVS Caremark, to perform the actual work of adjudicating claims and paying pharmacies. The ” ” occurred in the financial gap between these entities. CVS Caremark would bill Envolve a negotiated rate for a drug. Envolve would then bill the Centene MCO a significantly higher price for the same drug. The Centene MCO would report this higher price to the state as a “medical cost.”

The Mechanics of the Spread

The financial between what the state was charged and what the pharmacy received is known as “spread pricing.” While spread pricing is not inherently illegal in all contexts, the allegations against Centene focused on the deceptive nature of the spread within a Medicaid managed care environment. In Ohio, Attorney General Dave Yost’s investigation uncovered that Centene’s subsidiary, Buckeye Health Plan, utilized two separate internal PBMs, Envolve and Health Net, to administer benefits. This duplication appeared to serve no clinical or administrative purpose other than to insert additional of cost.

Auditors found that the cost per prescription for Buckeye Health Plan was substantially higher than other managed care plans operating in Ohio. The investigation revealed that the internal PBMs were retaining of the Medicaid reimbursement. For example, if a pharmacy dispensed a generic medication and was owed $10, CVS Caremark might bill Envolve $12 (including a small processing fee). Envolve, yet, would bill the Centene MCO $35 for that same claim. The MCO would pay Envolve $35 and report that amount to the state as the cost of the drug. The $23 difference, the spread, remained within the Centene corporate umbrella, recorded as revenue for Envolve rather than a reduction in cost for the state.

This method had a secondary, equally lucrative effect regarding the Medical Loss Ratio (MLR). Federal and state regulations generally require Medicaid MCOs to spend at least 85% of the revenue they receive from the state on actual medical care (the “medical loss”). Administrative costs and profits are capped at 15%. If an MCO spends less than 85% on care, it must rebate the difference to the state. By categorizing the “spread” retained by Envolve as a drug cost (a medical expense) rather than an administrative fee, Centene could artificially its reported medical spending. This accounting maneuver allowed the company to meet its MLR requirements and avoid paying rebates to the state, converting administrative profit into “medical spend” on the ledger.

Subcontractor Obfuscation and the CVS Connection

The role of subcontractors was pivotal to the opacity of the scheme. Envolve Pharmacy Solutions did not always maintain its own independent network of pharmacies or claims processing infrastructure in every market. Instead, it relied heavily on agreements with CVS Caremark and Express Scripts. In instances, Envolve acted as a repricing agent. When a Medicaid beneficiary filled a prescription, the data flowed from the pharmacy to CVS Caremark’s systems. CVS Caremark adjudicated the claim, determining eligibility and the payment amount to the pharmacy. CVS then sent the bill to Envolve.

State auditors faced a “black box” when attempting to verify these costs. When states requested data on pharmacy payments, Centene provided the amounts paid by the MCO to Envolve. Because Envolve was a related party, these figures represented an internal transfer of funds, not the market price of the drugs. The actual payments to the pharmacies, the “true” cost, were held in the data systems of the subcontractor (CVS Caremark). Centene allegedly resisted providing the granular, claim-level data from the subcontractor, arguing that Envolve’s contracts with the MCOs were the only relevant financial documents. This resistance prevented state actuaries from seeing the spread.

In Ohio, the investigation highlighted that Buckeye Health Plan’s use of both Envolve and Health Net created a “web of subcontractors” that made it nearly impossible for the Department of Medicaid to track the flow of tax dollars. The Attorney General’s lawsuit noted that this structure resulted in “significant breaches of contract,” including requests for reimbursement for amounts already paid by third parties and the artificial inflation of dispensing fees. The complexity was not a byproduct of; it was a design feature intended to shield the spread from regulatory scrutiny.

The Health Net and Envolve Merger Context

The structural capability to execute this scheme expanded significantly following Centene’s acquisition of Health Net in 2016. This merger brought Health Net’s internal PBM capabilities under the Centene umbrella. Subsequently, Centene integrated these operations with its existing US Script subsidiary to form Envolve Pharmacy Solutions. This consolidation gave Centene a massive internal engine for processing pharmacy claims across its expanding Medicaid footprint. The company marketed Envolve as a solution to “transform the traditional pharmacy benefit delivery model,” yet the allegations suggest it was used to entrench the traditional opacity of PBM pricing.

The of the operation was immense. In California, the Department of Justice found that between January 2017 and December 2018, Centene’s managed care plans reported inflated costs for prescription drugs. The investigation revealed that Centene leveraged its PBM contracts to save its plans approximately $2. 70 per prescription drug claim. Yet, instead of passing these savings to the state’s Medi-Cal program, the company retained the difference. With millions of prescriptions filled annually, small per-claim spreads accumulated into hundreds of millions of dollars in overcharges.

Regulatory Blind Spots and Data Manipulation

The success of the scheme depended on the inability of state regulators to penetrate the corporate veil between the MCO and its PBM affiliate. Standard state audits frequently focused on the MCO’s direct expenses. Since the MCO paid Envolve according to the contract terms, the payments appeared legitimate on the surface. The fraud, or “contract breach” as in civil settlements, lay in the fact that the MCO failed to disclose that it was paying a premium to a related party for services that were largely subcontracted.

also, the specific contract terms between Envolve and the subcontractors (CVS/Express Scripts) were frequently shielded by confidentiality agreements. This prevented states from comparing the rates Envolve paid to the rates Envolve charged. In Mississippi, the investigation by the State Auditor and Attorney General focused on this “convoluted flow of money.” The settlement of $55. 5 million in Mississippi was a direct result of piercing this and identifying the gap between the reported costs and the actual pharmacy reimbursements.

The “No-Fault” settlements Centene reached, $88. 3 million in Ohio, $55. 5 million in Mississippi, and subsequent payouts in Arkansas, Illinois, and other states, did not include an admission of liability. Yet, the remedial actions required by these agreements confirm the nature of the scheme. As part of the settlements, Centene agreed to restructure its PBM operations. The company committed to moving to a “transparent” model where the PBM charges the actual cost of the drug plus a fixed administrative fee, eliminating the spread. This shift acknowledges that the previous model, built on and spread pricing, was fundamentally incompatible with the transparency required for public fund stewardship.

The anatomy of this scheme reveals a calculated exploitation of the fragmented healthcare supply chain. By inserting a wholly-owned middleman between the insurer and the actual claims processor, Centene created a method to siphon Medicaid funds under the guise of medical expenses. The of Envolve and Health Net did not improve patient care or pharmacy access; it served primarily as a financial siphon, redirecting taxpayer money into corporate reserves through unclear pricing spreads and subcontracted services.

Spread Pricing Mechanics: How Differential Reimbursement Rates Inflated Medicaid Costs

The Mechanics of the Spread: A Financial Shell Game

At the core of the allegations against Centene Corporation lies a billing practice known in the industry as “spread pricing.” While the term suggests a standard margin for business operations, investigations by state auditors and attorneys general revealed a method that functioned less like a service fee and more like an arbitrage scheme. The model relied on a simple yet unclear differential: the price a pharmacy benefit manager (PBM) billed the state Medicaid program versus the significantly lower price it reimbursed the pharmacy for dispensing the drug. The PBM pocketed the difference. In Centene’s case, this spread was not a fractional operational cost, according to state findings, a massive, hidden profit center that siphoned hundreds of millions of dollars from taxpayer-funded healthcare safety nets.

Ohio: The Rosetta Stone of PBM Overbilling

The mechanics of this pricing strategy were laid bare in 2018 by Ohio Auditor Dave Yost, whose investigation provided the granular look at the of the spread. Yost’s team analyzed Medicaid prescription data and discovered that PBMs were charging the state a spread of over 31% on generic drugs, nearly four times the average spread observed in other sectors. The raw numbers illustrated the magnitude of the extraction. Between April 2017 and March 2018, PBMs managing Ohio’s Medicaid pharmacy benefits collected $224. 8 million in spread pricing fees. Of this total, $208 million was generated specifically from generic prescriptions. The state paid $662. 7 million for these generic drugs, meaning that for every dollar the state spent on generics, nearly 32 cents went directly to the PBMs rather than to the pharmacies or the cost of the medication itself. This differential reimbursement rate decoupled the cost of care from the bill presented to the taxpayer.

Replicating the Model: A Multi-State Pattern

The Ohio findings were not an anomaly a blueprint. Subsequent investigations in Mississippi, Arkansas, Illinois, and Kansas uncovered identical patterns, suggesting a widespread corporate strategy rather than regional mismanagement. * **Mississippi:** The state’s investigation found that Envolve Pharmacy Solutions, Centene’s PBM subsidiary, charged the Division of Medicaid amounts that exceeded allowed price caps. The spread here contributed to a $55. 5 million settlement, with state officials noting that the PBM model allowed the company to hide behind a “convoluted flow of money and numbers.” * **Arkansas and Illinois:** In these states, the method involved not just the spread on the drug ingredient cost also the manipulation of dispensing fees. Attorneys General Leslie Rutledge and Kwame Raoul alleged that Centene’s subsidiaries submitted inaccurate reimbursement requests that failed to disclose available pharmaceutical discounts and artificially inflated dispensing fees. The combined settlements for these two states alone totaled over $71 million. * **Kansas:** Attorney General Derek Schmidt’s investigation concluded that Centene failed to pass on negotiated drug price savings to the state. The company would secure a lower price from a manufacturer or pharmacy continue to bill the state at a higher, pre-negotiated rate, retaining the savings. This practice led to a $27. 6 million settlement.

The Granular Impact: The $2. 70 Metric

While the aggregate millions paint a picture of widespread extraction, the California investigation provided a specific metric that highlights the per-transaction nature of the scheme. The California Department of Justice found that between January 2017 and December 2018, Centene leveraged its PBM contracts to save its managed care plans approximately $2. 70 per prescription. Under a transparent pass-through model, these savings should have accrued to the state’s Medi-Cal program. Instead, investigators alleged that Centene failed to report or pass on these savings, charging the state $2. 70 more per script than the actual cost incurred. When multiplied across the millions of prescriptions filled for Medi-Cal beneficiaries, this small per-unit spread metastasized into a liability that resulted in a record $215 million settlement, the largest civil settlement of its kind in California history.

The Transparency Void

The persistence of this spread pricing model depended entirely on a absence of transparency. Contracts between state Medicaid agencies and Managed Care Organizations (MCOs) like Centene frequently absence clauses requiring full disclosure of pharmacy reimbursement rates. This contractual opacity allowed Envolve to operate in a “black box,” where the state saw only the final bill, not the itemized payments to the dispensing pharmacies. State officials were blind to the real market price of the drugs they were purchasing. When Envolve subcontracted with other PBMs, such as CVS Caremark, the pricing data became even further removed from state oversight. The “spread” thrived in this gap between the reported cost and the actual transaction price. It was only when auditors demanded access to the raw pharmacy payment data—comparing the PBM’s bill to the state against the pharmacy’s bank deposit—that the differential was exposed. This differential reimbursement strategy fundamentally distorted the economics of state Medicaid programs. It incentivized the PBM to prioritize drugs with the highest spread chance rather than the lowest in total cost, aligning corporate profit motives against the fiscal interests of the state. The hundreds of millions of dollars recovered in settlements serve as a retroactive correction to a pricing model that, for years, treated state treasuries as an unchecked revenue source.

The Ohio Catalyst: Inside the $88.3 Million Settlement that Triggered National Scrutiny

The Filing: A Direct Strike on the Black Box

On March 11, 2021, Ohio Attorney General Dave Yost filed a lawsuit that shattered the customary silence surrounding pharmacy benefit manager (PBM) operations in Medicaid. Filed under seal in the Franklin County Court of Common Pleas, the complaint targeted Centene Corporation and its subsidiaries, specifically Buckeye Health Plan, Envolve Pharmacy Solutions, and Health Net Pharmacy Solutions. Yost did not frame the case as a mere contract dispute or a clerical error. He characterized the company’s actions as a deliberate conspiracy to “fleece taxpayers” through a complex “shell game” designed to obfuscate the true cost of prescription drugs.

The lawsuit marked a departure from the tentative regulatory inquiries that had previously defined state interactions with managed care organizations. Yost alleged that Centene had breached its Medicaid contracts not through simple negligence, through a sophisticated architectural design intended to extract unearned revenue. The complaint asserted that Centene’s subsidiary, Buckeye Health Plan, had subcontracted its pharmacy benefit services to another wholly owned subsidiary, Envolve, which in turn subcontracted to yet another Centene entity, Health Net Pharmacy Solutions. This multi- structure, according to the Attorney General, served no clinical or administrative purpose other than to costs and hide profit margins from state auditors.

State investigators found that this “web of subcontractors” allowed Centene to bill the Ohio Department of Medicaid for amounts that exceeded the actual payments made to pharmacies. The lawsuit detailed specific allegations of “spread pricing” tactics, where the PBM retains the difference between what it bills the state and what it pays the dispensing pharmacy. Yost’s office claimed this practice cost Ohio millions of dollars in duplicate fees and artificial markups. The Attorney General’s public statement was blunt: “Centene used sophisticated moves to bill unearned dollars , moves known only at the top levels of health care companies.”

The method: Anatomy of the $20 Million Markup

The core of the Ohio allegations rested on the redundancy of the PBM services. While Buckeye Health Plan ostensibly paid Envolve and Health Net to manage pharmacy benefits, the actual claims processing and network management were largely handled by a third party, CVS Caremark. The lawsuit revealed that in 2017 alone, a Centene-owned PBM received approximately $20 million from the state for work that was performed by CVS Caremark. This duplication meant the state paid twice for the same administrative function, once to the external vendor and again to Centene’s internal subsidiaries.

This ” ” scheme created a fog of war around drug pricing. When the Ohio Department of Medicaid attempted to audit pharmacy costs, the multiple tiers of subcontractors made it nearly impossible to track a dollar from the state treasury to the local pharmacy counter. Each in the chain offered an opportunity to add a markup or a dispensing fee. The investigation uncovered instances where Centene’s entities artificially inflated dispensing fees, the amount paid to pharmacists for filling a prescription, and pocketed the difference. The state alleged that these fees were reported to Medicaid as legitimate provider costs when they were, in reality, retained profits for the managed care organization.

The financial impact was immediate and measurable. By inserting its own subsidiaries between the taxpayer and the pharmacy, Centene could control the data flow and the pricing logic. The Attorney General’s office noted that this arrangement allowed the company to file reimbursement requests for amounts already paid by third parties, double-dipping into the Medicaid fund. The opacity of the system was not a bug a feature, designed to prevent the state from verifying whether it was receiving the discounts and rebates it was contractually owed.

The Settlement: $88. 3 Million Without Admission

The legal battle ended almost as quickly as it began. On June 14, 2021, just three months after the initial filing, Centene agreed to pay $88. 3 million to the State of Ohio to settle the lawsuit. The speed of the resolution signaled the company’s desire to contain the damage and prevent a prolonged public discovery process that could expose internal communications and pricing algorithms. As is standard in such high- corporate settlements, the agreement included a clause stating that Centene did not admit to any liability or wrongdoing.

Attorney General Yost, while accepting the no-fault terms, made his interpretation of the payment clear. “I accept an apology note that has a dollar sign and zeroes after it,” he told reporters. The $88. 3 million recovery represented one of the largest settlements ever secured by a state attorney general against a pharmacy benefit manager. It also included non-monetary terms that forced a structural change in how Centene operated in the state. The company agreed to restructure its PBM relationships, moving towards a model where Envolve would act as an administrative service provider rather than a risk-bearing PBM, theoretically increasing transparency for the state.

The settlement unsealed the initial complaint, placing the specific allegations of and double-billing into the public record. This transparency proved more damaging to Centene’s reputation than the financial penalty itself. The detailed breakdown of how the “shell game” operated provided a roadmap for other states to examine their own Medicaid contracts. The Ohio case demonstrated that the complexity of PBM contracts could be pierced by aggressive litigation and forensic accounting.

The Domino Effect: Triggering a National Audit

Ohio’s $88. 3 million recovery acted as a catalyst for a nationwide re-evaluation of Medicaid managed care. The settlement provided proof of concept for other state attorneys general who had long suspected that PBMs were siphoning value from public health funds absence the evidence to prove it. Almost immediately following the Ohio announcement, Mississippi Attorney General Lynn Fitch finalized a similar settlement with Centene for $55. 5 million, based on comparable allegations of overbilling and absence of transparency.

The twin settlements in Ohio and Mississippi forced Centene to acknowledge a broader liability. The company subsequently established a $1. 1 billion reserve fund (later adjusted) to cover chance settlements in other states, a tacit admission that the practices identified in Ohio were not incidents part of a widespread operational model. This reserve fund signaled to investors and regulators alike that the “Ohio model” of investigation would likely be replicated across the country.

States such as Arkansas, Georgia, Kansas, and New Mexico launched their own inquiries, using the Ohio complaint as a template for their investigations. The scrutiny shifted the power between states and managed care organizations. Medicaid directors, previously reliant on PBM-provided data, began demanding raw claims data and independent audits. The Ohio settlement ended the era of “trust verify” in Medicaid pharmacy benefits, replacing it with a new standard of “verify then trust.”

The Ohio case also prompted a shift in Centene’s corporate strategy. In an effort to get ahead of the regulatory wave, the company announced it would problem a Request for Proposals (RFP) to outsource its pharmacy benefit management, eventually awarding a massive contract to Express Scripts. This move was widely interpreted as an attempt to distance the core insurance business from the toxic reputation its internal PBM arm had acquired. By the very structure Yost had attacked, the internal “web of subcontractors”, Centene attempted to close the chapter on the controversy, the financial and reputational aftershocks continued to shape the industry for years.

Key Element	Details of the Ohio Case
Plaintiff	Ohio Attorney General Dave Yost
Filing Date	March 11, 2021
Settlement Amount	$88. 3 Million
Primary Allegation	Use of multi- subcontractors (Envolve, Health Net) to costs and obfuscate fees.
Specific Tactic	Billing for services already paid to third parties; artificial inflation of dispensing fees.
Strategic Outcome	Centene restructured Envolve into an administrative service provider; established ~$1. 1B reserve for future settlements.

On June 14, 2021, the State of Mississippi announced a $55. 5 million settlement with Centene Corporation. This agreement resolved allegations that the company’s pharmacy benefit manager subsidiary, Envolve Pharmacy Solutions, had systematically overbilled the Mississippi Division of Medicaid. The settlement arrived simultaneously with an $88. 3 million agreement in Ohio. These twin resolutions marked a decisive moment in the scrutiny of managed care organizations. Mississippi Attorney General Lynn Fitch and State Auditor Shad White presented the deal as a victory for transparency. They secured a significant financial recovery without the uncertainty of a prolonged trial. The speed of this resolution underscored the strength of the evidence gathered by state investigators and their outside counsel.

The Investigation: Outsourcing the Audit

The route to the $55. 5 million recovery began in 2019. Mississippi State Auditor Shad White initiated a probe into the unclear financial flows of the state’s Medicaid program. The complexity of pharmacy benefit management contracts frequently exceeds the auditing capacity of standard government agencies. PBMs operate within a “black box” of proprietary data. They shield their pricing formulas and rebate structures from direct oversight. White recognized this asymmetry. He retained the Ridgeland-based law firm Liston & Deas to conduct a specialized forensic audit.

Liston & Deas brought a specific methodology to the investigation. They did not review contract compliance. They analyzed the raw claims data to identify discrepancies between the amounts billed to the state and the amounts paid to local pharmacies. This method allowed the firm to reconstruct the financial architecture of Envolve’s operations. The investigation focused on the years 2017 and 2018. It sought to determine if Envolve had adhered to the strict price caps and reimbursement limits established in its contract with the Division of Medicaid.

The decision to hire outside counsel on a contingency basis changed the of the oversight. It aligned the financial interests of the investigators with the recovery of taxpayer funds. Liston & Deas utilized a team of data analysts and economists to parse millions of transaction records. This forensic capability proved essential. The standard reporting provided by PBMs frequently aggregates data in ways that obscure specific profit margins on individual drug claims. By piercing this veil, the investigators instances where the state paid a premium that never reached the pharmacy counter.

Anatomy of the Allegations

The findings of the Mississippi investigation mirrored the structural problem identified in Ohio. The core allegation centered on “spread pricing.” This practice involves a PBM charging the health plan a higher price for a medication than it pays the dispensing pharmacy. The PBM retains the difference as profit. While spread pricing is not inherently illegal in all contexts, the Mississippi investigation alleged that Envolve’s practices violated specific regulatory caps and transparency requirements within the Medicaid contract.

Attorney General Fitch described the scheme with blunt force. She stated that the settlement ended the days of “hiding behind a convoluted flow of money and numbers.” The allegations extended beyond simple spread pricing. Investigators found evidence of ” ” fees. This occurs when multiple subsidiaries within the same corporate umbrella charge administrative fees for the same transaction. Envolve allegedly inflated dispensing fees and failed to disclose the true net cost of pharmacy services. These practices siphoned millions of dollars from the Medicaid fund. That money was intended to provide healthcare for the state’s most residents.

The investigation also examined whether Envolve had “double-dipped” on reimbursements. This involves submitting claims for amounts that had already been covered by third parties or other funding streams. The granular analysis performed by Liston & Deas exposed these redundancies. It provided the state with the use necessary to demand a substantial repayment. The sheer volume of the data made it difficult for Centene to dismiss the findings as clerical errors or incidents. The pattern of billing suggested a widespread strategy to maximize revenue through obfuscation.

The Pre-Litigation Settlement Strategy

Centene chose to settle the Mississippi claims before a formal lawsuit was filed. This “pre-litigation” strategy allowed the corporation to control the narrative and limit the disclosure of sensitive internal documents. A public trial would have required the discovery phase. That process could have placed internal emails, strategy documents, and unredacted contracts into the public record. By settling early, Centene avoided a detailed judicial examination of its PBM mechanics.

The agreement contained a standard “no-fault” clause. Centene denied any liability for the practices described in the settlement. The company maintained that its operations were compliant with all applicable laws and contracts. In a public statement, Centene emphasized its commitment to “transparency” and its restructuring of Envolve. The company framed the settlement as a business decision to resolve a dispute and move forward. This narrative sought to reassure investors that the problem was a legacy problem rather than an ongoing operational risk.

The timing of the Mississippi settlement was strategic. It coincided exactly with the Ohio announcement. This coordination suggests a high-level decision by Centene’s leadership to “clear the decks” of state-level PBM liabilities. The company established a $1. 1 billion reserve fund to cover these and future settlements. This accounting maneuver signaled to the market that Centene anticipated further claims had the financial resources to absorb them. The $55. 5 million payment to Mississippi represented a fraction of this reserve. Yet it was one of the largest civil settlements in the history of the Mississippi State Auditor’s office.

The Role of Liston & Deas

The success of the Mississippi investigation elevated the profile of Liston & Deas. The firm created a blueprint for holding PBMs accountable. Their model involved combining legal aggression with sophisticated data analytics. They demonstrated that states could recover substantial sums by auditing the “spread” in managed care contracts. This success did not go unnoticed. Other states began to look at the Mississippi and Ohio results as a proof of concept.

The firm’s compensation reflected the high of the litigation. Under their contract with the Mississippi Attorney General, Liston & Deas received approximately $2. 8 million from the settlement proceeds. This fee structure incentivized the firm to maximize the recovery. It also insulated the state from the upfront costs of a complex corporate investigation. Critics of contingency fees in government litigation that it outsources enforcement to private profit-seekers. Supporters counter that state agencies absence the resources to fight multi-billion dollar corporations without such partnerships.

The involvement of Liston & Deas also carried a political dimension. Reports surfaced regarding the firm’s connections to former Mississippi Governor Haley Barbour. Barbour also served as a lobbyist for Centene. This intersection of legal, political, and corporate interests added a of intrigue to the proceedings. yet, the tangible result of the investigation, a $55. 5 million return to the state treasury, validated the effectiveness of the audit. The firm’s work provided a template that would soon be replicated in states like Arkansas, Kansas, and New Mexico.

Transparency and Future Compliance

The settlement agreement imposed strict transparency requirements on Centene’s future operations in Mississippi. The company agreed to provide the Division of Medicaid with full visibility into the adjudication and payment of pharmacy claims. This meant that state officials would no longer have to guess the true cost of a drug. They would be able to see exactly what the pharmacy was paid. This transparency is serious for ensuring that Medicaid funds are used.

Centene also committed to restructuring its PBM relationships. The company announced that Envolve would operate as an administrative service provider rather than a traditional PBM. This shift was intended to eliminate the spread pricing model in favor of a pass-through pricing model. In a pass-through model, the PBM charges the state the exact amount it pays the pharmacy plus a fixed administrative fee. This structure removes the incentive to drug prices to capture the spread.

The Mississippi settlement served as a warning shot to the entire PBM industry. It demonstrated that states were no longer to accept “black box” pricing models. The collaboration between the Attorney General, the State Auditor, and private counsel proved to be a formidable enforcement method. It exposed the vulnerabilities in the managed care model and set a precedent for the wave of litigation that followed. The $55. 5 million recovery was significant. Yet the long-term impact lay in the exposure of the mechanics of overbilling.

Summary of the Mississippi Settlement

The announcement on February 8, 2023, by California Attorney General Rob Bonta marked a definitive moment in the state’s ongoing battle against corporate healthcare fraud. Centene Corporation agreed to pay $215, 392, 758 to resolve allegations that it overcharged the Medi-Cal program for pharmacy services. This settlement stands as the largest civil recovery of its kind in California history regarding pharmacy benefit manager practices. The agreement concluded a multi-year investigation into the conduct of Centene’s subsidiaries, specifically California Health & Wellness and Health Net. These entities manage healthcare services for millions of Medi-Cal beneficiaries. The state’s investigation exposed a systematic failure to report accurate drug costs. This failure resulted in the state paying significantly more for pharmaceutical benefits than necessary.

The method of Inflated Reporting

State investigators focused their inquiry on a specific two-year period from January 2017 to December 2018. During this window, Centene’s managed care plans allegedly submitted inflated prescription drug cost reports to the California Department of Health Care Services. The core of the deception involved the gap between the costs Centene incurred and the costs it reported to the state. Centene used its vertically integrated pharmacy benefit manager to negotiate discounts with dispensing pharmacies. These negotiations yielded significant savings. The Attorney General’s office determined that Centene saved approximately $2. 70 per prescription drug claim through these internal arrangements. Under normal regulatory expectations, these savings should have been disclosed to the state or passed down to the Medi-Cal program. Centene did neither.

The subsidiaries instead reported the higher, pre-discount prices as their actual costs. This reporting practice concealed the $2. 70 margin on every prescription filled. By reporting inflated costs, the companies manipulated the data used by the state to determine reimbursement levels and capitation rates. Medi-Cal relies on accurate historical cost data to set future payment rates for managed care plans. When a plan reports artificially high costs, the state may set future rates higher than necessary to cover those supposed expenses. This creates a pattern where the state overpays for services based on falsified data points. The California Department of Justice concluded that this practice violated the California False Claims Act. The act prohibits knowingly presenting false claims for payment or using false records to get a claim paid by the state.

Vertical Integration as a Cloaking Device

The allegations against Centene in California highlight the opacity afforded by vertical integration. Centene acquired Health Net in 2016. The violations by the Attorney General began in January 2017. This timeline suggests that the parent company rapidly implemented its preferred pharmacy benefit management structures upon assuming control of the California insurer. In this model, the insurance plan and the pharmacy benefit manager operate under the same corporate umbrella. This relationship allows the parent company to shift money between subsidiaries while presenting a unified, albeit distorted, financial picture to regulators. The insurance arm pays the pharmacy benefit arm an inflated price. The pharmacy benefit arm pays the actual pharmacy a lower price. The difference remains within the parent company as profit. When the insurance arm reports its “costs” to the state, it reports the inflated payment made to its sister company rather than the actual market price paid for the drug.

This internal transfer pricing method allows the company to claim it is meeting Medical Loss Ratio requirements. These requirements mandate that insurers spend a certain percentage of revenue on patient care. By paying its own subsidiary inflated prices, the insurer appears to spend more on medical care than it actually does. The California investigation pierced this corporate veil. Investigators from the Division of Medi-Cal Fraud and Elder Abuse tracked the actual flow of funds and identified the undisclosed discounts. The $2. 70 per script variance, when multiplied across the millions of prescriptions filled for Medi-Cal beneficiaries, accumulated into a massive liability. The settlement amount of $215 million represented twice the value of the actual loss calculated by the state. This punitive multiplier signals the severity with which the California Department of Justice viewed the deception.

The Role of State Agencies

The recovery required coordination across multiple state regulatory bodies. The California Department of Justice led the legal charge. The Department of Health Care Services provided the necessary data analysis to quantify the overcharges. The Department of Managed Health Care and the Department of Insurance also assisted in the resolution. This multi-agency method was necessary due to the complex regulatory environment governing Medi-Cal managed care plans. Attorney General Bonta emphasized that such overcharges drain resources from the state’s safety net. Medi-Cal serves the state’s most economically disadvantaged residents. Diverting funds through inflated reporting reduces the resources available for actual patient care. The settlement agreement ensured full restitution to the Medi-Cal program. The funds returned to the state allow for the continued financing of health services for low-income Californians.

Legal and the “No-Fault” Clause

Centene agreed to the settlement without admitting liability. The company maintained that its practices were lawful and that the settlement was a business decision to avoid the uncertainty of prolonged litigation. A company spokesperson described the deal as a “no-fault agreement” and reaffirmed the corporation’s commitment to transparency. This refusal to admit wrongdoing is standard in large corporate settlements. It allows the company to resolve the legal threat without creating a binding legal precedent that could be used in other lawsuits. Yet the magnitude of the payment speaks to the strength of the state’s case. A $215 million payout is rarely agreed upon if the defendant believes they have a high probability of exoneration in court. The settlement also resolved the state’s claims under the False Claims Act, closing the door on further state-level prosecution for this specific conduct during the specified time period.

Operational Context and Market Dominance

Health Net and California Health & Wellness hold a dominant position in the California Medicaid market. They provide coverage to residents in over 20 counties. The of their operations means that even small discrepancies in per-unit reporting result in massive aggregate costs to the state. The $2. 70 margin per prescription might appear negligible in isolation. In the context of millions of claims processed annually, it represents a significant revenue stream. The investigation revealed that this revenue stream was built on a foundation of obfuscation. The state’s ability to recover these funds demonstrates the increasing sophistication of regulatory auditors. State officials are better equipped to analyze the complex financial relationships between insurers and their pharmacy benefit managers. They can identify when a “cost” is actually a profit margin disguised as a medical expense.

Comparison to National Trends

The California settlement fits into a broader pattern of scrutiny facing Centene across the United States. While the mechanics of “spread pricing” and inflated reporting appear in various state investigations, the California case is notable for its sheer size. The $215 million recovery exceeds the settlements reached in states like Ohio and Mississippi. This difference reflects both the size of the California market and the aggressive posture of the California Department of Justice. The state’s investigation did not rely on the findings of other states. It conducted an independent forensic analysis of the claims data submitted by Health Net and California Health & Wellness. This independent verification was essential for establishing the specific damages under California law. The settlement serves as a warning to other managed care organizations operating in the state. It establishes that the state possesses the capability and the to audit the internal transfer pricing of vertically integrated health companies.

The Aftermath and Future Oversight

Following the settlement, the California Department of Health Care Services has intensified its oversight of pharmacy benefit manager contracts. The state has moved toward a model that reduces the opacity of these arrangements. The transition to “Medi-Cal Rx,” a system where the state directly manages pharmacy benefits, was in part driven by the desire to eliminate the “black box” of PBM pricing. By taking direct control of the pharmacy benefit, the state aims to remove the incentive for managed care plans to reported costs. The Centene settlement provided a retrospective validation of this policy shift. It demonstrated the financial risks inherent in allowing private insurers to self-report drug costs without rigorous transparency requirements. The recovery of over $215 million returned taxpayer dollars to the public trust. It also sent a message that the era of unquestioned acceptance of PBM cost reporting has ended. The state demands a clear accounting of the actual acquisition costs of medications. The days of hiding profits within the spread are over in the California Medi-Cal environment.

The investigation into Centene’s practices in California also highlighted the role of whistleblowers. While the California Department of Justice led the public announcement, the complexities of PBM billing are frequently brought to light by insiders who understand the coding and reporting method. The settlement

The Florida settlement remains an outlier in the national pattern of Centene recoveries. While the financial penalty was consistent with the company’s liability in other large states, the diversion of funds to a politically active nonprofit introduced a dimension of governance risk that went beyond simple healthcare economics. It revealed that in the high- environment of Medicaid contracting, the resolution of fraud allegations can sometimes serve as a vehicle for political financing.

Invoking the Texas Medicaid Fraud Prevention Act

The legal engine driving this settlement was the Texas Medicaid Fraud Prevention Act, a statute designed to recover funds lost to deceptive practices within the state’s healthcare system. Unlike simple contract disputes, the TMFPA allows the state to pursue civil penalties for acts that result in unauthorized payments. Texas investigators alleged that Centene’s PBM engaged in deceptive reporting methods that obscured the actual acquisition costs of medications. By submitting inflated pricing data, the company reportedly secured higher reimbursement rates than the market value of the drugs warranted. Attorney General Paxton’s office focused on the transparency requirements in state law. The investigation suggested that Centene’s vertical integration, where the insurer (Superior HealthPlan) and the PBM (Envolve) operate under the same corporate umbrella, created an environment ripe for pricing manipulation. The state argued that this structure allowed the company to bypass checks and balances that exist when an insurer contracts with an independent PBM. The $165. 6 million recovery was not a refund of overpayments a penalty intended to signal the state’s intolerance for unclear billing method.

The Mechanics of the Alleged Overbilling

While the specific evidentiary details remain sealed under the terms of the agreement, the allegations in Texas mirrored those in other jurisdictions. The core accusation involved “spread pricing” and the failure to pass through negotiated discounts. In a typical spread pricing model, a PBM charges the health plan a higher price for a drug than it pays the pharmacy to dispense it, keeping the difference as profit. When the PBM and the health plan are owned by the same parent company, this spread becomes an internal transfer of state funds that the reported administrative costs of the Medicaid managed care organization (MCO). In Texas, the sheer size of the Medicaid population, Superior HealthPlan covers over 1. 3 million members, magnified the financial impact of these per-prescription spreads. Even a gap of a few dollars per claim into tens of millions of dollars in excess costs over a fiscal year. The Attorney General’s investigation sought to determine whether Centene had systematically misrepresented these costs to the Texas Health and Human Services Commission, so circumventing the Medical Loss Ratio (MLR) requirements that mandate a certain percentage of funds be spent on patient care rather than administrative overhead or profit.

Strategic Settlement and “No-Fault” Resolution

Consistent with its national legal strategy, Centene settled the Texas allegations without admitting liability. The agreement explicitly states that the company maintains its business practices were lawful. This “no-fault” clause allows the corporation to resolve the financial liability without establishing a legal precedent that could be used in future litigation or criminal proceedings. The $165. 6 million payment was drawn from the $1. 25 billion reserve Centene established in 2021 to address PBM-related liabilities across multiple states. The timing of the settlement reveals the complex interplay between legal accountability and corporate operations. The deal was signed on July 11, 2022, yet it was not publicly announced until September 19, 2022. During this interim period, Texas regulators renewed a major contract with Superior HealthPlan to provide healthcare services to children. This sequence of events, settling a massive fraud investigation while simultaneously securing a lucrative government contract, demonstrates the entrenched position of Centene within the state’s safety net infrastructure. Critics that the reliance of state Medicaid programs on a few dominant MCOs makes it difficult for regulators to impose the sanction of contract termination, even in the face of serious financial allegations.

Political and Financial

Attorney General Paxton framed the settlement as a victory for fiscal responsibility. “Protecting taxpayer funds and the financial integrity of the Texas Medicaid Program is a top priority for my office,” Paxton stated in the official release. “The results we achieved in this case send a clear message to providers that Texas expects transparency from its Medicaid partners as required by Texas law.” The financial distribution of the settlement reflects the shared funding structure of Medicaid. Because the federal government matches state Medicaid spending, a portion of the $165. 6 million recovery must be returned to Washington. The exact spl on the Federal Medical Assistance Percentage (FMAP) applicable during the years the alleged overbilling occurred. For Texas, this means that while the headline figure is substantial, the net benefit to the state’s general revenue is significantly lower, likely just under half of the total amount. This resolution also served as a bellwether for other states with large Medicaid populations. At the time of the announcement, the Texas settlement was the largest single-state recovery Centene had agreed to, surpassing the amounts paid to Ohio ($88. 3 million) and Mississippi ($55. 5 million). It signaled that states with higher enrollment numbers and more aggressive fraud control units could extract significantly larger penalties. The Texas benchmark likely influenced the subsequent negotiations in California, which eventually resulted in an even larger $215 million settlement.

Operational Continuity for Superior HealthPlan

Even with the magnitude of the payment, Superior HealthPlan’s operations in Texas continued without interruption. The settlement agreement did not mandate structural changes to the company’s PBM relationships, nor did it require the divestiture of Envolve. Instead, the resolution functioned as a retrospective financial correction. The company emphasized its commitment to “local, simple, and transparent” healthcare delivery in its public statements, framing the settlement as a necessary step to put legacy problem to rest and focus on future growth. The Texas case highlights the limitations of financial penalties in altering corporate behavior when the entity is a widespread component of the state’s healthcare apparatus. While the TMFPA provided the use to recover nine figures in taxpayer money, the underlying market that allowed for the alleged overbilling, specifically the vertical integration of insurers and PBMs, remain largely intact. The settlement closed the book on past claims left open the question of whether current oversight method are sufficient to prevent similar pricing disparities in the future.

Midwest and Southern Expansion of the Settlement Wave

By late 2021, the investigative momentum generated by Ohio and Mississippi had breached the containment lines Centene attempted to establish. The scrutiny moved into the American South and Midwest, targeting state-specific Medicaid contracts managed by Centene subsidiaries. Kansas and Arkansas, two states with distinct political yet similar Medicaid managed care structures, announced settlements totaling $42. 8 million within months of each other. These agreements did not represent financial recoupment. They exposed the widespread nature of the ” ” and spread pricing strategies employed by Envolve Pharmacy Solutions across jurisdictional boundaries. The synchronized nature of these resolutions suggests a coordinated effort by state attorneys general, aided by outside counsel, to the unclear billing structures that had siphoned millions from taxpayer-funded healthcare programs.

The timing of these settlements reveals a strategic capitulation by the St. Louis-based healthcare giant. Rather than face prolonged discovery phases that might unearth granular details of their pricing algorithms, Centene opted to liquidate these liabilities through “no-fault” agreements. This method allowed the corporation to maintain its contracts and avoid admitting to civil fraud while paying out sums that, while significant to state budgets, represented a fraction of their annual revenue. The Kansas and Arkansas cases specifically highlighted how Envolve Pharmacy Solutions manipulated the reporting of drug costs to state regulators, blinding oversight agencies to the true cost of pharmaceutical benefits.

Arkansas: The Envolve-CVS Subcontract Loophole

On September 30, 2021, Arkansas Attorney General Leslie Rutledge announced a $15. 2 million settlement with Centene. This resolution specifically targeted the operations of Arkansas Total Care, a Centene subsidiary, and its PBM arm, Envolve Pharmacy Solutions. The investigation focused on a specific timeframe between 2017 and 2018, a period where the internal mechanics of Centene’s PBM operations underwent significant shifts. The Arkansas inquiry unearthed a serious method of the alleged overbilling: the use of a subcontract with CVS Caremark to obscure actual drug costs.

State investigators found that Envolve had subcontracted its pharmacy payment responsibilities to CVS Caremark. Under normal transparency standards, the state Medicaid program should receive data reflecting the actual amounts paid to pharmacies for dispensing drugs. The investigation revealed a different reality. Envolve reported inflated pharmacy costs to the Arkansas Medicaid program. These reported figures did not match the lower amounts actually paid to pharmacies through the CVS Caremark subcontract. Envolve retained the difference between the inflated report and the actual payment. This practice, known as spread pricing, was hidden behind the administrative wall of the subcontract.

The Arkansas settlement required Centene to pay the state $15, 228, 318. 72. Beyond the monetary penalty, the agreement mandated a shift in business practices. Centene agreed to provide full transparency regarding the adjudication and payment of pharmacy benefit claims. This included disclosing the exact amount paid to the pharmacy for each pharmaceutical claim, eliminating the “black box” that allowed the spread to exist. Attorney General Rutledge characterized the settlement as a necessary step to stop “predatory pharmacy benefit managers” from gouging the state. The resolution in Arkansas served as a template for identifying how subcontracts could be used to filter and cost data before it reached state regulators.

Kansas: Sunflower Health Plan and the $27. 6 Million Recovery

Two months after the Arkansas announcement, Kansas Attorney General Derek Schmidt publicized a $27. 6 million settlement on December 6, 2021. This agreement resolved allegations against Centene and its local subsidiary, Sunflower Health Plan. The Kansas investigation was broader in temporal scope than the Arkansas inquiry, covering conduct from 2016 through late 2021. This extended timeline partly explains the higher settlement amount compared to Arkansas. The allegations in Kansas mirrored those in other states placed heavy emphasis on the fiduciary failure of the managed care organization.

Attorney General Schmidt’s office alleged that Centene failed to satisfy its obligation to represent the state’s best interests during negotiations with pharmaceutical suppliers. The core of the complaint centered on the concealment of discounts. Centene and Envolve secured lower prices and rebates from drug manufacturers and pharmacies did not pass these savings on to the Kansas Medicaid program. Instead, they monetized the opacity of their reporting systems. The state accused Centene of artificially inflating dispensing fees and failing to accurately report the true cost of pharmacy services. This manipulation meant that while the state believed it was reimbursing for the cost of care, it was actually subsidizing Centene’s profit margins on each prescription filled.

The Kansas settlement included a significant payout to the private law firm Liston & Deas. The firm, which had been instrumental in the Ohio and Mississippi settlements, received approximately 15 percent of the Kansas recovery. This fee arrangement highlights the reliance of state attorneys general on specialized outside counsel to navigate the complex actuarial and legal labyrinths constructed by PBMs. The involvement of Liston & Deas confirms that the Kansas investigation was part of the broader, multi-state strategy that used the findings in Ohio to use settlements across the country.

The Mechanics of “unclear Reporting”

A unifying theme in both the Kansas and Arkansas settlements was the weaponization of data reporting. In both states, the Medicaid agencies, the Kansas Department of Health and Environment and the Arkansas Department of Human Services, relied on data provided by the managed care organizations to set capitation rates and monitor program health. The investigations revealed that the data streams provided by Envolve were fundamentally compromised. By aggregating costs or failing to break down the components of a drug claim (ingredient cost, dispensing fee, rebate), Envolve prevented state actuaries from seeing the true market price of the drugs.

In Kansas, the Attorney General noted that Centene’s strategies kept the state “in the dark” about true prices. This absence of visibility is not an administrative oversight. It is a prerequisite for spread pricing to function. If a state knows that a generic drug costs $2. 00, it not agree to reimburse $10. 00. By reporting a bundled or inflated cost, the PBM creates an artificial baseline. The settlements in Kansas and Arkansas forced Centene to agree to provide access to granular data, theoretically restoring the state’s ability to audit claims line-by-line. This shift from unclear, aggregate reporting to transaction-level transparency represents the most significant structural outcome of these legal battles.

The “No-Fault” Shield and Corporate Strategy

even with the severity of the allegations, ranging from inflated dispensing fees to the concealment of millions in discounts, neither settlement included an admission of liability. Centene consistently maintained that its practices were lawful and that the settlements were agreed upon to avoid the uncertainty and cost of litigation. In statements following the announcements, the company emphasized its commitment to “local, simple, and transparent” healthcare delivery. This “no-fault” structure is a serious component of Centene’s defense strategy. By settling without admission, the company protects itself from the collateral damage that a fraud verdict would inflict, such as chance debarment from federal healthcare programs or shareholder lawsuits alleging management misconduct.

The financial impact of these settlements on Centene was negligible in the context of its total revenue, yet the reputational and operational costs were cumulative. The $42. 8 million paid to Kansas and Arkansas contributed to the $1. 25 billion reserve the company set aside for such disputes. For the states, yet, the funds represented a significant recovery of misappropriated tax dollars. In Kansas, the recovery was directed to the state treasury and federal payback obligations, while Arkansas utilized the funds to replenish the Medicaid trust.

Comparative Analysis of State Recoveries

The between the Kansas ($27. 6 million) and Arkansas ($15. 2 million) settlements warrants examination. While both states faced similar overbilling schemes, the Kansas investigation covered a five-year period, whereas the Arkansas settlement focused primarily on the 2017-2018 window involving the specific CVS subcontract. while the mechanics of the fraud were consistent, the duration and specific contractual vehicles varied by state. The Kansas settlement also reflected a more aggressive of “failure to represent best interests” claims, a broader legal theory than the specific pricing inaccuracies in Arkansas.

These two settlements demonstrated that the PBM overbilling scandal was not an incident in Ohio or Mississippi a widespread operational model exported to every market where Centene held a Medicaid contract. The unraveling of these schemes in the Midwest and South proved that the ” ” of subcontractors was a deliberate corporate strategy designed to extract maximum profit from the complex flow of Medicaid pharmaceutical funds. As these settlements were finalized, they paved the way for subsequent investigations in states like Georgia and Texas, where the financial would prove to be even higher.

The Death of the Spread

For decades, spread pricing served as the primary profit engine for PBMs operating in the Medicaid space. Centene’s subsidiaries, particularly Envolve Pharmacy Solutions, used this method to generate unclear margins, billing state taxpayers significantly higher rates for generic medications than the reimbursement provided to dispensing pharmacies. The exposure of these practices in 2021 and 2022 rendered the model politically and legally toxic. State Medicaid directors, previously reliant on MCOs to manage drug spend with minimal oversight, pivoted rapidly. The regulatory consensus shifted toward a “pass-through” pricing model. Under this framework, the PBM must bill the state the exact amount paid to the pharmacy, the “acquisition cost” plus a professional dispensing fee. The PBM’s revenue is restricted to a transparent, flat administrative fee per claim, eliminating the incentive to drug costs or under-reimburse pharmacies to widen the spread.

Ohio’s Single PBM Experiment

Ohio, the epicenter of the initial exposure, led the structural revolution. Following the discovery that PBMs had extracted $224 million in spread pricing fees in a single year, the Ohio Department of Medicaid (ODM) terminated the pharmacy management authority of individual MCOs. On October 1, 2022, Ohio launched the Single Pharmacy Benefit Manager (SPBM) program, contracting exclusively with Gainwell Technologies to manage pharmacy benefits for all Medicaid enrollees. This consolidation stripped Centene’s Buckeye Health Plan and other MCOs of their ability to route pharmacy claims through related-party PBMs. The SPBM model unbundled the pharmacy benefit, allowing the state to set uniform reimbursement rates and maintain full visibility into drug costs. In its two years, the SPBM structure reportedly saved Ohio taxpayers $333 million while increasing dispensing fees paid to independent pharmacies by over 1, 200%, stabilizing the rural pharmacy network that spread pricing had decimated.

The Carve-Out Counterstrike: New York and California

While Ohio centralized PBM management, other states chose to “carve out” the pharmacy benefit entirely, removing it from the managed care capitation rates and returning to a Fee-For-Service (FFS) model administered directly by the state. New York executed this transition on April 1, 2023, with the implementation of **NYRx**. By removing the pharmacy benefit from MCOs like Centene’s Fidelis Care, New York aimed to recapture the manufacturer rebates that MCOs and their PBMs had previously retained or obscured. The state projected annual savings exceeding $400 million by eliminating the spread and contracting directly with pharmacies. This move severed the revenue stream Centene had relied upon for its New York operations, forcing a recalibration of its profit expectations in the state. California followed a similar trajectory with **Medi-Cal Rx**, transitioning all pharmacy services from managed care to a state-administered FFS system. Although the transition faced initial technical blocks, it permanently removed the “black box” of PBM pricing from the equation. also, the enactment of **Senate Bill 41**, January 1, 2026, codified the ban on spread pricing for all PBMs contracting with state-regulated health plans, ensuring that the practice could not migrate to the commercial sector to offset Medicaid losses.

Federal Codification and the 2025 Legislation

The state-level rebellion coalesced into federal mandates by 2025. The **Protecting Pharmacies in Medicaid Act** and provisions within the **One Big Beautiful Bill Act (OBBBA)**, signed into law in July 2025, imposed a nationwide ban on spread pricing in Medicaid managed care. These federal statutes require all PBMs to report actual drug costs and pass through 100% of manufacturer rebates to the state or federal government. The legislation also introduced strict Medical Loss Ratio (MLR) definitions, preventing MCOs from classifying PBM “spread” as a medical expense to meet the 85% spending requirement. This loophole closure forced insurers to operate on legitimate medical margins rather than financial engineering.

Financial Aftershocks

The transition to pass-through pricing and the loss of rebate retention inflicted severe damage on Centene’s balance sheet. In October 2025, the corporation reported a quarterly loss of $6. 6 billion, driven in part by a $6. 7 billion non-cash goodwill impairment. This write-down reflected the diminished value of its managed care contracts in a post-spread environment. Without the ability to subsidize low capitation rates with hidden pharmacy profits, Centene was forced to “reprice” its portfolio for the 2026 contract year. The company’s leadership acknowledged that the “spread” was no longer a viable revenue stream, signaling a permanent shift to a low-margin, administrative-fee-based business model for its pharmacy services.

The regulatory confirms that the Centene settlements were not legal events the catalyst for a widespread correction. The era of the “black box” PBM is over, replaced by a regime of enforced transparency where profit must be earned through administrative efficiency rather than arbitrage.

The South Carolina Resolution

South Carolina remained one of the significant holdouts in the multi-state settlement framework until late 2023. Attorney General Alan Wilson secured a **$25. 9 million** agreement to resolve allegations that Centene’s subsidiaries, including Absolute Total Care, misrepresented the true cost of pharmacy services provided to the state’s Medicaid program. The investigation focused on the familiar pattern where the PBM failed to disclose the net cost of prescription drugs, pocketing the difference between what the state paid and what was dispensed to pharmacies. The South Carolina inquiry specifically targeted the opacity of the sub-contractor arrangement. State auditors found that the PBM structure allowed Centene to retain discounts that should have been passed on to the South Carolina Department of Health and Human Services. By settling, Centene avoided a protracted legal battle that could have forced the public disclosure of its internal pricing algorithms. The $25. 9 million payout, while substantial, represents a fraction of the state’s total Medicaid drug spend, yet it serves as a retroactive correction for years of unclear billing.

Indiana: The $66. 5 Million Clawback

In January 2023, Indiana Attorney General Todd Rokita announced a **$66. 5 million** settlement, one of the largest in the second wave of recoveries. The Indiana investigation went deeper than mere spread pricing; it alleged that Centene inflated dispensing fees, the amount paid to pharmacies for the professional service of filling a prescription. By artificially inflating these fees on the reporting side while paying pharmacies a lower rate, the PBM allegedly created a surplus that was not returned to the state. The Indiana settlement required Centene to pay the full amount in two installments over 12 months. Crucially, the investigation highlighted that these practices occurred while Centene was acting as a fiduciary for the state’s Medicaid funds. The between the reported costs and the actual costs incurred by the PBM formed the basis of the state’s claim under the Indiana False Claims Act, although the “no-fault” settlement structure allowed the corporation to resolve the matter without admitting to statutory violations.

New Mexico and the ” ” Accusation

New Mexico’s investigation, led by Attorney General Hector Balderas, provided one of the clearest descriptions of the ” ” scheme. The state secured a **$13. 7 million** settlement in June 2022. Balderas’s office explicitly accused Centene of ” fees”, a process where multiple subsidiaries (such as Envolve and Health Net Pharmacy Solutions) are stacked between the payer and the pharmacy. Each extracts a seemingly nominal administrative fee, which cumulatively results in significant inflation of the final cost billed to Medicaid. The New Mexico settlement included a mandate for complete pricing transparency, a non-monetary concession that states began to demand after realizing that financial penalties alone were insufficient to alter PBM behavior. The ” ” terminology used by New Mexico regulators offered a precise vocabulary for what other states had simply termed “overbilling,” stripping away the corporate euphemisms to describe a method designed to obscure the flow of tax dollars.

The Breadth of the Liability Map

Beyond the headline cases, the list of settling states demonstrates the geographic of the PBM strategy. * **Iowa:** Attorney General Tom Miller secured **$44. 4 million** in December 2022. The investigation found that Centene failed to disclose retail discounts, meaning the state paid list prices while the PBM negotiated rebates that it kept. The settlement proceeds were split between the state and the federal government, reflecting the joint funding structure of Medicaid. * **Louisiana:** The state recovered **$64. 2 million**, a figure that places it among the highest tier of settlements, comparable to Florida and Illinois. * **Oregon:** A **$17 million** settlement addressed allegations that Centene’s Trillium Community Health Plan failed to pass through required pharmacy discounts. * **Nebraska and Nevada:** These states secured **$29. 4 million** and **$11. 3 million** respectively, closing out their inquiries into similar “failure to disclose” allegations.

The $1. 25 Billion Reserve: A Strategic Cap

When Centene announced a **$1. 25 billion** reserve for legal settlements in 2021, the market reacted with relief rather than panic. This figure, while astronomical to the average taxpayer, allowed the corporation to quantify its liability and reassure investors that the PBM scandal had a finite price tag. The aggregate total of the settlements across Ohio, Mississippi, Texas, Washington, California, and the states detailed above has largely tracked against this reserve. This financial maneuvering reveals a clear reality of modern corporate jurisprudence: the “no-fault” settlement is a commodity. By setting aside a billion dollars, Centene purchased immunity from a court ruling that could have established a legal precedent regarding PBM fiduciary duties. In every single jurisdiction, from the $215 million record in California to the $13. 7 million in New Mexico, Centene admitted no liability. The corporation maintained that its practices were lawful and that the settlements were to avoid the distraction of litigation.

The Federal Shadow and Future

While the state-level civil settlements are largely concluded, the federal remain a lingering variable. Medicaid is a joint state-federal program, meaning that for every dollar Centene overbilled a state, the federal government (via the Centers for Medicare & Medicaid Services) also incurred a loss. Most state settlements included provisions to return the “federal share” of the recovery to Washington. Yet, the Department of Justice and the Office of Inspector General (OIG) retain the authority to investigate the widespread nature of these practices under the False Claims Act. The series of settlements has forced a structural shift in the industry. states have moved to “pass-through” pricing models or single-PBM systems to eliminate the spread pricing gaps that Centene exploited. The opacity that allowed Envolve to generate outsized margins has been replaced, in jurisdictions, by rigid transparency requirements.

Final Analysis

The investigation into Centene’s PBM practices exposes a fundamental in the privatized Medicaid model. For nearly a decade, a major managed care organization allegedly used complex corporate structures—, spread pricing, and unclear subcontracting—to arbitrage the difference between public funding and pharmacy reimbursements. The recovery of over **$1 billion** by state attorneys general represents a significant victory for oversight, yet it also highlights the magnitude of the funds that were diverted from patient care to corporate ledgers. The “no-fault” nature of these resolutions leaves the question of legality unanswered in the courts, the financial data speaks with absolute clarity: the states demanded their money back, and Centene paid.